HOME >> MEDICINE >> NEWS
Treatment response to Aricept® (donepezil hydrochloride) not predicted by Apolipoprotein E4 genotype or gender

WASHINGTON, D.C. 11 July, 2000 -- Aricept® (donepezil hydrochloride) demonstrated beneficial effects on cognition and global function over the course of one year in a double-blind, placebo-controlled, multinational study in patients with mild to moderate Alzheimer's disease (AD). In this study, treatment response was not predicted by Apolipoprotein E4 (ApoE4) genotype and/or gender, according to data presented today at the World Alzheimer Congress in Washington D.C.

ApoE is a lipoprotein that carries cholesterol in the blood. The exact role the ApoE4 allele plays in the pathogenesis of AD or in the memory decline of cognitively impaired elderly is unclear presently. Furthermore, much of the evidence concerning a correlation between ApoE4 copy number and the pathological features of AD (e.g. neuronal plaque density and the appearance of neurofibrillary tangles) is contradictory. It has been suggested that patients carrying an ApoE4 allele may have a more severe cholinergic deficit than those who do not.

"The reports of associations between ApoE4 genotype, gender and response to cholinesterase inhibitor therapy in AD patients are conflicting. In this recently completed study, a secondary analysis showed that the treatment response to ARICEPT®, a cholinesterase inhibitor, was not predicted by ApoE4 genotype and/or gender in patients with mild to moderate AD," says Hilkka Soininen, M.D., Ph.D., University of Kuopio, Kuopio, Finland.

This one-year multinational, double-blind, placebo-controlled study enrolled 286 patients with mild to moderate AD from 28 sites in five Northern European countries (Denmark, Finland, Norway, Sweden and The Netherlands). Patients were randomized to receive either ARICEPT® (n=142; 5 mg/day for 28 days, and then 10 mg/day) or placebo (n=144) for one year. The mean age of the patients enrolled in the study was 72.5 (range: 49-88 years).

Outcomes measures included evaluation of global function (the Gottf
'"/>

Contact: Celeste Torello, Pfizer Inc.
212-733-6471
Porter Novelli
10-Jul-2000


Page: 1 2

Related medicine news :

1. Treatment of cardiac lesions without anaesthesic
2. Treatment guidelines for kids with bipolar disorder published
3. University of Washington joins new Autism Treatment Network to provide better medical services
4. Treatment for brain tumor does not always follow recommendations
5. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
6. Treatment of ductal carcinoma in situ varies widely in United States
7. Treatment options expand for patients with neuropathic pain
8. Treatment interruption shows no benefit in drug-resistant HIV infection
9. Peanut Allergy: Major Advances in Treatment and Education
10. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
11. Treatment helped reduce dose of inhaled corticosteroids while maintaining asthma control

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology:
Cached News: